<DOC>
	<DOCNO>NCT01681979</DOCNO>
	<brief_summary>Asthma report affect 3-14 % pregnancy make asthma medicine one commonly used class medicine pregnancy . Maternal asthma particular poorly control asthma find associated number adverse perinatal outcome include preterm delivery , low birth weight pre-eclampsia . At present little know safety human many anti-asthma medicine use pregnancy . As result inhaled corticosteroid , exception budesonide category B , FDA pregnancy category C , indicative fact adequate well controlled study human . Fluticasone propionate inhale corticosteroid use treatment asthma , often combination long-acting Î²-agonist salmeterol . Owing small number pregnancy exposure past , little known safety fluticasone propionate use pregnancy . A recent feasibility study , however , show sufficient number first trimester expose pregnancy General Practice Research Database ( GPRD ) allow overall risk major congenital malformation ( MCMs ) evaluate . This study also demonstrate use data GPRD possible determine individual 's exposure anti-asthma medicine pregnancy classify treatment term British Thoracic Society treatment step base link prescription primary care data . The aim study 1 ) evaluate safety profile fluticasone propionate ( FP ) compare exposure inhale corticosteroid major congenital malformation combine primary endpoint , whilst take account potential confounders exposure anti-asthma medicine ; 2 ) test null hypothesis exposure fluticasone propionate first trim pregnancy associate increase overall risk major congenital malformation compare risk expose inhaled corticosteroid first trim pregnancy . The study retrospective cohort study use data United Kingdom 's General Practice Research Database ( GPRD ) . The GPRD contain longitudinal medical record collect within UK primary care . All medical symptom diagnosis record database , include relate pregnancy , form Read Codes . In addition cod data GPs option record un-coded comment ( 'free text ' ) , detailed description diagnose treatment along information provide via hospital letter , referral discharge summary . As record stillbirth , neonatal death pre-term birth GPRD verify , verification exercise carry . This involve request review free text comment 100 stillbirth , 100 neonatal death 100 pre-term birth . Free text comment request associated medical code related pregnancy , delivery , post natal visit , death , post mortem , hospital letter form communication . If free text find informative send questionnaires woman 's GP . All outcome identify verified blind asthma treatment severity level .</brief_summary>
	<brief_title>WEUSRTP4850 : Phase II : ICS/LABA Use Pregnancy Outcomes</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>female patient whose pregnancy register GPRD start end 1 January 2000 31 December 2010 Patients consider asthma base diagnosis prescription cod patient registered practice contribute uptostandard data GPRD 6 month start pregnancy , throughout pregnancy 3 month follow pregnancy end date . patient 1150 year age pregnancy start date patient experience multiple birth ( twin , triplet ) patient medical code diagnosis chronic obstructive pulmonary disease ( COPD ) chronic respiratory condition ( e.g . cystic fibrosis ) record anytime pregnancy end date</criteria>
	<gender>Female</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>fluticasone propionate</keyword>
	<keyword>asthma</keyword>
	<keyword>pregnancy</keyword>
	<keyword>major congenital malformation</keyword>
</DOC>